Compare · DRAD vs SLNO
DRAD vs SLNO
Side-by-side comparison of Digirad Corporation (DRAD) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRAD and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO carries a market cap of $2.76B.
- SLNO has hit the wire 39 times in the past 4 weeks while DRAD has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for DRAD).
- Company
- Digirad Corporation
- Soleno Therapeutics Inc.
- Price
- -
- $53.02+0.08%
- Market cap
- -
- $2.76B
- 1M return
- -
- +0.76%
- 1Y return
- -
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2014
- News (4w)
- 0
- 39
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest DRAD
- SEC Form 8 filed
- Digirad Corporation to Present at Investor Conferences in November
- Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2020
- Digirad Corporation to Release Third Quarter 2020 Financial Results on November 13
- Digirad Corporation to Sell DMS Health for $18.75 Million
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)